Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0027627 (metastases)
 103,950 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

5-S-cysteinyldopa has been demonstrated in the plasma of two patients with metastases of malignant melanoma and a high excretion rate of 5-S-cysteinyldopa in the urine. In one patient the plasma clearance of 5-S-cysteinyl dopa was 30 ml/min and in the other 69 ml/min. These clearance values were 43 and 45%, respectively, of the creatinine clearance in the two patients.
 ...
PMID:5-S-cysteinyldopa in the plasma of melanoma patients and the renal clearance of this amino acid. 4 73

Xeno-antisera, prepared by immunization with soluble membrane material obtained from melanoma tumours and partially purified by column chromatography, were found to detect an antigenic specificity common to some tumour extracts and sera of melanoma patients. The presence of this antigen in patients' sera allows speculation for its possible use for early diagnosis of metastases and its role in the blocking of the immunological defences of the melanoma patients. Preparation of monospecific antisera by immunization with insoluble serum-antigen/antibody complexes has been successfully undertaken.
 ...
PMID:Identification of an antigen associated with malignant melanoma. 5 Feb 97

The results of treatment of two groups of patients with primary melanoma are compared. 25 patients in group 1 were treated by wide local excision of the primary melanoma, and 23 in group 2 were treated by vaccination with live vaccinia virus 14 days before wide local excision. Vaccination exerts a favourable effect on the course of melanoma both in terms of survival and prolongation of the interval between treatment of the primary lesion and subsequent development of metastases.
 ...
PMID:Treatment of primary melanoma by intralesional vaccinia before excision. 5 9

The leukocyte adherence inhibition (LAI) test has been used to assess specific anti-tumour immunoreactivity in 80 patients with malignant melanoma, 21 of whom had apparently been successfully treated by surgery, and 44 control subjects. Reaction with melanoma extracts in vitro enabled the activity of blood leukocytes to be detected by inhibition of their adherence to glass, while serum was tested for factors which modified this inhibition. Of the patients with tumours (ranging from primary melanoma in situ to advanced disseminated disease), 22/24 had active leukocytes and 50/58 has serum blocking factor; two of the sera, from patients with regressing tumours were unblocking. After surgery with no clinical recurrence, leukocytes continued to be active except when tested several years after operation. Blocking factor rapidly disappeared in 16/20 patients tested, and in several patients examined serially the serum became unblocking. In three cases, persistence of serum blocking was followed by clinical diagnosis of metastases. Leukocyte activity was nerver detected in control subjects (0/10), many of whom had other kinds of tumours or skin lesions. Blocking activity in serum was found in only 3/38 controls with no history of melanoma (1 had a fibrosing cellular blue naevus and 2 had liver disease). Thus the LAI test correlated well with clinical and pathological findings, and shows great promise for the reliable, rapid and specific immunodiagnosis of malignant melanoma.
 ...
PMID:Leukocyte adherence inhibition and specific immunoreactivity in malignant melanoma. 5 36

With the aid of gas chromatography and mass spectrometry a metabolite of dopa, 3-methoxytyrosine, has been demonstrated in the urine of 2 patients with melanoma metastases, the amounts excreted being 4.0 mg and 8.5 mg/24 hours, respectively. 3-Methoxytyrosine could not with certainty be identified in the urines of two normal subjects.
 ...
PMID:Demonstration of 3-methoxytyrosine in the urine of melanoma patients. 5 53

16 of 35 patients (46%) with malignant melanoma were found to have cytoplasmic oestrogen-receptor activity in biopsy specimens. OEstrogen-receptor activity was detected in primary lesions, lymph-node metastases, skin metastases, and visceral metastases. Equal percentages of males and females had positive assays. Scatchard analysis of binding in one case was consistent with a single class of high affinity receptor sites.
 ...
PMID:Oestrogen receptors in human malignant melanoma. 6 May 69

A newly discovered amino acid, 5-S-cysteinyldopa, present in the urine of healthy subjects is excreted in pathological amounts in many patients suffering from melanoma metastases. Increased excretion of 5-S-cysteinyldopa may be observed before metastases become clinically evident. Determination of 5-S-cysteinyldopa is superior to determination of dopa+dopamine in the diagnosis of melanoma metastases.
 ...
PMID:5-S-cysteinyldopa in the urine of melanoma patients. 7 2

Metastases to the hand are rare. Most frequently they result from carcinomas of the lung, breast or kidney. This is a case report of a rare peripheral metastatic lesion in a 24-year-old man with melanoma. There are no previously reported hand metastases from melanoma. Because of the extremely poor prognosis for patients with osseous metastases from melanoma, treatment should be palliative.
 ...
PMID:Hand metastasis from melanoma: a case study. 8 15

The adaptation of the principles of electrocoagulation to controlling symptomatic cutaneous metastatic disease is discussed. The technique permits minimal anesthesia, excellent hemostasis, local control, satisfactory cosmesis with reduced hospitalization. Two illustrative cases are reported of metastatic malignant melanoma and metastatic leiomyosarcoma.
 ...
PMID:Electrocoagulation: palliative surgery to control metastatic cutaneous malignancy. 8 49

Surgery has continuously improved the prognosis of malignant melanoma but not in case of metastases. Widespread metastases are only accessible to palliative chemotherapy. This paper deals with therapy by Dacarbazin in 19 patients suffering from metastazising malignant melanoma. Dacarbazin increases our limited feasibilities in treating advanced malignant melanoma.
 ...
PMID:[Dacarbazin -- therapy of metastazising malignant melanoma (author's transl)]. 9 12


1 2 3 4 5 6 7 8 9 10 Next >>